Literature DB >> 25973799

The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative survey.

Kathleen Lang1, Ivy M Alexander, James Simon, Matthew Sussman, Iris Lin, Joseph Menzin, Mark Friedman, David Dutwin, Andrew G Bushmakin, Maia Thrift-Perry, Corrado Altomare, Ming-Ann Hsu.   

Abstract

BACKGROUND: Little is known about the prevalence and cumulative burden of coexisting health conditions including chronic joint and muscular pain, urinary incontinence (UI), depression, osteoporosis risk, moderate/severe vasomotor symptoms, and vulvar/vaginal atrophy (VVA). We surveyed a nationally representative U.S. sample of midlife (age 40-64 years) women to ascertain the prevalence, general health-related quality of life (HRQoL), and health-seeking behaviors associated with these six conditions.
METHODS: This cross-sectional, telephone survey collected data from a sample of English- and Spanish-speaking U.S. women. The survey contained demographic and menopausal status questions, and also five condition-specific symptom/disease risk-screening instruments. The EuroQol 5 dimensions (EQ-5D) questionnaire was used to measure HRQoL. Health-seeking behavior was measured based on clinician discussion of and recent treatment for each condition.
RESULTS: Three thousand fifty eight women (mean age 53.4 years) completed the survey. The majority were white (75.6%), married (60.5%), employed full- or part-time (59.0%), and postmenopausal (69.8%; based on self-report). The prevalence [95% confidence interval] of 0, 1, 2, and ≥3 conditions was 35.2% [33.5-36.9], 34.2% [32.5-35.9], 17.9% [16.6-19.3], and 12.7% [11.5-13.9], respectively. Osteoporosis risk (30.6%) was most prevalent, followed by VVA (27.8%) and UI (26.6%). UI and VVA coexisted most frequently (11.3%), followed by osteoporosis risk and VVA (9.8%). EQ-5D scores decreased with increasing number of illnesses (0, 1, 2, and ≥3 conditions, means: 0.92, 0.87, 0.77, 0.61, respectively; p<0.01). Health-seeking behavior varied by condition.
CONCLUSION: Over 25% of women surveyed had multiple coexisting conditions. Lower HRQoL was associated with multiple conditions and with each added condition.

Entities:  

Mesh:

Year:  2015        PMID: 25973799      PMCID: PMC4440998          DOI: 10.1089/jwh.2014.4907

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  39 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

Review 2.  Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D.

Authors:  Stephen J Walters; John E Brazier
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

3.  Relationship between multimorbidity and health-related quality of life of patients in primary care.

Authors:  Martin Fortin; Gina Bravo; Catherine Hudon; Lise Lapointe; José Almirall; Marie-France Dubois; Alain Vanasse
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

4.  The PHQ-9: validity of a brief depression severity measure.

Authors:  K Kroenke; R L Spitzer; J B Williams
Journal:  J Gen Intern Med       Date:  2001-09       Impact factor: 5.128

5.  Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995.

Authors:  Jo Jones; William Mosher; Kimberly Daniels
Journal:  Natl Health Stat Report       Date:  2012-10-18

6.  Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry.

Authors:  S M Cadarette; S B Jaglal; N Kreiger; W J McIsaac; G A Darlington; J V Tu
Journal:  CMAJ       Date:  2000-05-02       Impact factor: 8.262

7.  The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence.

Authors:  Jeanette S Brown; Catherine S Bradley; Leslee L Subak; Holly E Richter; Stephen R Kraus; Linda Brubaker; Feng Lin; Eric Vittinghoff; Deborah Grady
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

8.  The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures.

Authors:  Robert D Langer; Emily White; Cora E Lewis; Jane M Kotchen; Susan L Hendrix; Maurizio Trevisan
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

9.  The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.

Authors:  Marcia L Stefanick; Barbara B Cochrane; Judith Hsia; David H Barad; James H Liu; Susan R Johnson
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

10.  The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants.

Authors:  Cheryl Ritenbaugh; Ruth E Patterson; Rowan T Chlebowski; Bette Caan; Lesley Fels-Tinker; Barbara Howard; Judy Ockene
Journal:  Ann Epidemiol       Date:  2003-10       Impact factor: 3.797

View more
  9 in total

1.  Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity.

Authors:  Susanne Schmitz; Tatjana T Makovski; Roisin Adams; Marjan van den Akker; Saverio Stranges; Maurice P Zeegers
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

2.  Impact of Chronic Medical Condition Development on Longitudinal Physical Function from Mid- to Early Late-Life: The Study of Women's Health Across the Nation.

Authors:  Brittney S Lange-Maia; Carrie A Karvonen-Gutierrez; Rasa Kazlauskaite; Elsa S Strotmeyer; Kelly Karavolos; Bradley M Appelhans; Imke Janssen; Elizabeth F Avery; Sheila A Dugan; Howard M Kravitz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-06-18       Impact factor: 6.053

Review 3.  Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies.

Authors:  Hai Nguyen; Gergana Manolova; Christina Daskalopoulou; Silia Vitoratou; Martin Prince; A Matthew Prina
Journal:  J Comorb       Date:  2019-08-22

Review 4.  Multidimensional screening for predicting pain problems in adults: a systematic review of screening tools and validation studies.

Authors:  Elke Veirman; Dimitri M L Van Ryckeghem; Annick De Paepe; Olivia J Kirtley; Geert Crombez
Journal:  Pain Rep       Date:  2019-09-11

5.  Multimorbidity among midlife women in India: well-being beyond reproductive age.

Authors:  Parul Puri; Abhinav Sinha; Pranab Mahapatra; Sanghamitra Pati
Journal:  BMC Womens Health       Date:  2022-04-12       Impact factor: 2.809

6.  How Does Sex Influence Multimorbidity? Secondary Analysis of a Large Nationally Representative Dataset.

Authors:  Karolina Agur; Gary McLean; Kate Hunt; Bruce Guthrie; Stewart W Mercer
Journal:  Int J Environ Res Public Health       Date:  2016-03-31       Impact factor: 3.390

7.  Assessment of lower urinary tract symptoms in different stages of menopause.

Authors:  Larissa Ramalho Dantas Varella; Rossânia Bezerra da Silva; Maria Clara Eugênia de Oliveira; Priscylla Hellouyse Angelo Melo; Técia Maria de Oliveira Maranhão; Maria Thereza Albuquerque Barbosa Cabral Micussi
Journal:  J Phys Ther Sci       Date:  2016-11-29

8.  Cardiopulmonary Resuscitation Training Disparities in the United States.

Authors:  Audrey L Blewer; Said A Ibrahim; Marion Leary; David Dutwin; Bryan McNally; Monique L Anderson; Laurie J Morrison; Tom P Aufderheide; Mohamud Daya; Ahamed H Idris; Clifton W Callaway; Peter J Kudenchuk; Gary M Vilke; Benjamin S Abella
Journal:  J Am Heart Assoc       Date:  2017-05-17       Impact factor: 5.501

Review 9.  Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women.

Authors:  Rossella E Nappi; Ellis Martini; Laura Cucinella; Silvia Martella; Lara Tiranini; Alessandra Inzoli; Emanuela Brambilla; David Bosoni; Chiara Cassani; Barbara Gardella
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-21       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.